On 13 June 2024, Adalvo announced its liraglutide pre-filled pen has been approved in the EU, making it the first EU approved generic liraglutide. Originator Novo Nordisk supplies liraglutide as Victoza® in EU which is indicated for the treatment of type 2 diabetes. Adalvo received approval via the decentralised procedure.
According to Adalvo’s announcement, Victoza achieved over $4.8 billion in global sales in 2023.
This news follows Biocon’s 27 March 2024 announcement of its approval of synthetic liraglutide in the UK.